Sorafenib is a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma

被引：0
|
作者：
Lapecorella, M. [1 ]
Napolitano, M. [1 ]
Tudini, M. [2 ]
Bruera, G. [2 ]
Lucchesi, A. [2 ]
Giordano, A., V [3 ]
Mariani, G. [1 ]
Ricevuto, E. [2 ]
机构：
[1] Univ Aquila, Haemophilia & Thrombosis Ctr, Laquila, Italy
[2] Univ Aquila, Dept Expt Med, Med Oncol, Laquila, Italy
[3] Univ Aquila, Dept Radiol, Laquila, Italy
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-TH-694
引用
收藏
页码：1167 / 1167
页数：1
相关论文
共 50 条
  • [1] Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma
    Lapecorella, M.
    Napolitano, M.
    Tudini, M.
    Bruera, G.
    Lucchesi, A.
    Giordano, A. V.
    Mariani, G.
    Ricevuto, E.
    [J]. HAEMOPHILIA, 2010, 16 (01) : 185 - 187
  • [2] The combination of the NT157 and sorafenib as a new therapeutic option for hepatocellular carcinoma.
    Gun, Hui
    Wang, Yu
    Yu, S. Z.
    Li, W. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Liver transplantation as a therapeutic option for hepatocellular carcinoma
    Matsunami, H
    Shimizu, Y
    Lynch, SV
    Balderson, GA
    Ando, Y
    Strong, RW
    [J]. ONCOLOGY, 2002, 62 : 82 - 86
  • [4] Therapeutic Drug Monitoring of Sorafenib in Hepatocellular Carcinoma Patients
    Thomas, Sachu
    Thankappan, Aneesh Prasanna
    Padma, Uma Devi
    Keechilat, Pavithran
    [J]. THERAPEUTIC DRUG MONITORING, 2020, 42 (02) : 345 - 347
  • [5] Adjutant therapeutic strategy for sorafenib-resistant hepatocellular carcinoma
    Peng, Syue-Wei
    Lin, Yi-Heng
    Teng, Ming-Hao
    Lai, Hung-Cheng
    Chang, Te-Sheng
    Huang, Yen-Hua
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [6] Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
    Zhang, Gong
    Wang, Yufeng
    Fuchs, Bryan C.
    Guo, Wei
    Drum, David L.
    Erstad, Derek J.
    Shi, Baomin
    DeLeo, Albert B.
    Zheng, Hui
    Cai, Lei
    Zhang, Liyuan
    Tanabe, Kenneth K.
    Wang, Xinhui
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
    Elizabeth A.Kuczynski
    Robert S.Kerbel
    [J]. 癌症, 2016, 35 (12) : 641 - 644
  • [8] Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
    Kuczynski, Elizabeth A.
    Kerbel, Robert S.
    [J]. CHINESE JOURNAL OF CANCER, 2016, 35 : 97
  • [9] Sorafenib in Hepatocellular Carcinoma
    Bajetta, Emilio
    Procopio, Giuseppe
    Colombo, Andrea
    Guadalupi, Valentina
    Verzoni, Elena
    Pietrantonio, Filippo
    Pusceddu, Sara
    Manzoni, Mariangela
    Gevorgyan, Arpine
    Buzzoni, Roberto
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 277 - 287
  • [10] Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?
    Liao, Ying-Yang
    Zhong, Jian-Hong
    Tong, Tie-Jun
    Peng, Ning-Fu
    Li, Le-Qun
    [J]. LIVER INTERNATIONAL, 2016, 36 (11) : 1715 - 1715
12345